title: Overcoming Hurdles to Development of a Vaccine against Pneumocystis jirovecii.
abstract: Development ofPneumocystispneumonia (PCP) is a common problem among immunosuppressed individuals. There are windows of opportunity in which vaccination would be beneficial, but to date, no vaccines have made it to clinical trials. Significant hurdles to vaccine development include host range specificity, making it difficult to translate from animal models to humans. Discovery of cross-reactive epitopes is critical to moving vaccine candidates from preclinical animal studies to clinical trials.
authors.affiliation: Department of Microbiology, Immunology and Molecular Genetics and Division of Infectious Diseases, University of Kentucky College of Medicine, Lexington, Kentucky, USA bgarv0@uky.edu.
authors.forename: Beth A
authors.initials: BA
authors.lastname: Garvy
mesh_terms: D000818:Animals; D005657:Fungal Vaccines / Q000276:immunology*; D006801:Humans; D045363:Pneumocystis carinii / Q000276:immunology*; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control*
chemical_list: D005657:Fungal Vaccines
keywords: Pneumocystis carinii; vaccines